DaVita: Dialysis Compounder on a Leash

The Quarter in Context

DaVita's second quarter of 2026, reported on the August 4, 2026 Form 10-Q, shows a steady-state healthcare operator rather than a quarter of inflection. Total revenue reached $3,554 million, up 5.2% year over year from $3,380 million in the second quarter of 2025, with six-month revenue of $6,970 million versus $6,603 million in the prior-year period. Dialysis patient service revenues of $3,366 million remained the engine, while "Other revenues" of $188 million contributed a smaller slice. Operating income of $579 million produced a 16.3% operating margin, up from 15.9% a year earlier. Net income attributable to DaVita of $265 million (diluted EPS of $4.02) was supported by a 21.1% effective tax rate and $150 million of debt expense, leaving the quarter as a confirmation of margin discipline rather than a surprise on either side of the consensus.

Working-capital dynamics swung meaningfully. Operating cash flow of $490 million in the quarter and $811 million for the first six months (versus $504 million a year earlier) reflects in part a recovery from a 2025 collection disruption tied to a third-party cybersecurity incident. Capital expenditure of $170 million in the quarter (split $123 million maintenance and $46 million development per the management free-cash-flow reconciliation) and $272 million for the half implies a capital intensity that is meaningful but not punitive for the model. Share repurchases of $181 million in the quarter reduced diluted weighted-average shares to 66.1 million from 77.4 million a year earlier, a 14.6% reduction that materially aids per-share growth even when total earnings grow modestly.

Business Model and Profit Engine

DaVita runs two reportable segments: U.S. dialysis (the dominant engine) and "Other — Ancillary services," which combines U.S. integrated kidney care (IKC), U.S. other ancillary services, and international operations. Within U.S. dialysis for the second quarter of 2026, Medicare and Medicare Advantage contributed $1,749 million in dialysis patient service revenue, Commercial payors added $1,076 million, and Other government payors added $325 million; Medicaid and Managed Medicaid added another $227 million. The same segment also earned $152 million of Medicare-related "Other revenue." Ancillary services produced $554 million of revenue for the quarter, with the largest sub-segment contribution coming from international operations and IKC. Patients pay indirectly through government and commercial insurers; the direct economic buyer is the payor, and the regulatory framework — CMS reimbursement, Medicare Advantage contracts, and the Comprehensive Kidney Care Contracting model — sets the price ceiling.

Recurring revenue is structural: roughly 200,500 U.S. dialysis patients are treated three times per week for life or until transplant, and the ESKD patient population has been growing at a low single-digit rate over the long run per USRDS data cited in the 10-K. Variable costs dominate the cost stack. Patient care costs of $2,392 million in the quarter (67.3% of revenue) include nursing, dialysis supplies, pharmaceuticals, and clinic-level overhead that flex with treatment counts; general and administrative of $423 million (11.9% of revenue) is largely fixed at the corporate level; depreciation and amortization of $168 million reflects prior capital deployment. Revenue therefore drops through to gross profit with relatively low marginal cost, giving operating leverage on volume and modest pricing. Capital intensity runs through property and equipment additions ($2,749 million net book value at June 30, 2026) and operating lease right-of-use assets ($2,430 million), and the management free-cash-flow definition subtracts both maintenance and development capex and adds or subtracts distributions from or to noncontrolling partners, a structure worth noting because roughly $1,561 million of noncontrolling interests subject to put provisions sit on the balance sheet. What could weaken this engine: any compression in commercial payor rates, a regulatory shift that bundles ESKD into Medicare Advantage at lower effective rates, and clinical innovation (the 10-K flags GLP-1 receptor agonists and SGLT2 inhibitors as potential long-run demand risks).

Earnings Quality and Cash Conversion

Where the issuer reports cash flow and capital expenditure cumulatively, the standalone-quarter cash-flow figures are derived by subtracting the preceding cumulative filing. They are calculations from SEC facts rather than separately reported quarterly line items. Earnings quality looks acceptable but not pristine. Net income for the quarter of $343 million (of which $78 million is attributable to noncontrolling interests) reconciles to operating cash flow of $490 million; depreciation of $181 million and stock-based compensation of $26 million are standard non-cash adds. The trailing-twelve-month operating cash flow of $2,193 million against net income of $847 million reflects the working-capital swing plus the depreciation add-back; subtracting capital expenditure of $170 million in the quarter (and $583 million on a trailing-twelve-month basis) yields a quarterly free-cash-flow proxy of $320 million and a trailing-twelve-month free-cash-flow figure of $1,610 million. This is an accounting free-cash-flow proxy — the filings do not separate maintenance from growth capex in the line items, so we cannot cleanly distinguish a maintenance-capex figure. Management's own free-cash-flow reconciliation for the half, which adjusts for noncontrolling-interests distributions and contributions, was $396 million, higher than the unadjusted version.

The gap between net income and cash from operations is wider than ideal, driven by large non-cash add-backs but also by large working-capital flows (accounts receivable grew by $24 million in the half despite revenue growing faster, and accrued compensation and benefits was paid down by $108 million). Stock-based compensation of $26 million in the quarter is a real economic expense that should not be ignored. A goodwill balance of $7,591 million against shareholders' equity deficit of $(765) million is striking — accumulated earnings turned positive by only $81 million at June 30, 2026, after years of buybacks, and treasury stock sits at $(788) million; this is a structurally levered equity story rather than a clean compounding one.

Business Quality, Moat, and Industry Position

On the available evidence, the company is best described as an important participant, not a demonstrated core supply-chain bottleneck. This classification describes strategic position only; it is not independent proof of a moat or valuation upside. DaVita operates as one of two scaled national outpatient dialysis networks in the United States, with 2,671 U.S. centers and 595 international centers at June 30, 2026. This is a meaningful scale advantage: nephrologist relationships, CMS quality ratings, supply contracts, and referral pipelines take years to build. The 10-K notes the company has been an industry leader in CMS's Quality Incentive Program for eleven consecutive years and in the Five-Star Quality Rating System for ten years. Whether that translates into durable pricing power is harder to verify from the filings alone — Medicare sets rates, and commercial payor rates are negotiated but typically constrained by Medicare Advantage benchmarks. The payor mix itself, with Medicare and Medicare Advantage at roughly 49% of U.S. dialysis patient service revenue in the quarter and Commercial at 30%, leaves the company with limited exposure to a single private payor.

The IKC segment is not yet a meaningful profit contributor, posting only $63 million of operating income on $554 million of ancillary revenue in the quarter. International operations are small but growing, with 595 centers across 14 countries serving approximately 94,500 patients as of year-end 2025. The competitive question is whether value-based care arrangements will shift margins favorably; the 10-K also flags GLP-1 receptor agonists and SGLT2 inhibitors as potential long-run demand displacement risks for ESKD dialysis. No supplier concentration disclosures were extracted, but the company mentions minimum purchase commitments for dialysis equipment, parts, pharmaceuticals, supplies and technology services in the 10-Q, which suggests some procurement concentration that we treat as a data gap.

Management and Capital Allocation

Management has run a clear capital-allocation playbook: lever up, buy back stock. Total debt at June 30, 2026 stood at $10,781 million in principal and discount-adjusted terms, with $117 million of current portion and $10,664 million long-term; the company holds $669 million of cash and $20 million of short-term investments against this. Diluted weighted-average shares fell from 79.3 million in the first half of 2025 to 67.5 million in the first half of 2026, a 15% reduction driven by treasury purchases totaling $761 million in the first six months of 2026 and $994 million in the comparable period of 2025. The company has $1,373 million remaining under repurchase authorizations as of July 31, 2026. No dividends are paid; capital return is exclusively buybacks.

This is a leveraged buyback story rather than a compounding story. The debt structure is concentrated in senior secured credit facilities (Term Loan A-2 at SOFR+1.50%, Term Loan B-2 at SOFR+1.75%, a $1.5 billion revolver with $65 million drawn) and senior notes maturing between 2030 and 2033, with a weighted average effective interest rate of 5.43% in the second quarter of 2026. Interest rate caps hedge $3,500 million of notional exposure through 2029, leaving roughly $898 million of floating-rate exposure. The Ninth Amendment to the credit agreement in June 2026 added $500 million to Term Loan B-2 to pay down revolver borrowings. Management has been net releveraging in 2026, with debt issuances net of repayments of $504 million in the half, but the share count is still falling faster than earnings growth would otherwise produce. The accounting result is a shareholders' equity deficit of $(765) million, driven by $788 million of treasury stock accumulated against a thin accumulated earnings balance of $81 million.

Valuation and What the Market Already Expects

The dated market snapshot (October 15, 2026) shows a market capitalization of $11,529 million against a free-cash flow proxy of $1,610 million trailing twelve months, an unlevered cash-flow yield of roughly 14% before any debt adjustment. The market is pricing in a free-cash-flow stream that is at best flat or shrinking modestly from the current run rate, even though observed revenue growth was 5.2% year over year in the second quarter. The implied growth rate embedded in the dated market capitalization is materially below the company's recent revenue trajectory, suggesting the market is either skeptical of growth durability or is capitalizing the cash flows at a demanding discount rate.

On a capital-cost view, the dated market capitalization sits more than 20% below the base-scenario fair value derived from a deterministic free-cash-flow-to-equity model that assumes a 4% first-five-year and 3% second-five-year free-cash-flow growth path, a 3% terminal growth rate, and a 9% discount rate. The market is therefore paying roughly $0.60 on the dollar relative to a base-case author calculation, which is the qualitative signal that a margin of safety may be present even without a separate re-derivation. The implication is that any sustained free-cash-flow growth above the low-single-digit range materially improves the implied return, while any growth disappointment would compress it. Because the same-date net-cash position is not available from the available balance-sheet snapshots, no balance-sheet adjustment is incorporated into the equity-value bridge, and the market-derived share count used in the deterministic calculation is approximately 63.8 million, lower than the 66.1 million of diluted weighted-average shares for the second quarter.

Ten-Year Cash Flow to Fair Market Value

The starting free cash flow is the normalized SEC cash-flow proxy, while every growth rate, discount rate and terminal rate below is an explicit editorial assumption rather than company guidance. Each annual cash flow is forecast and discounted separately; terminal value is year-ten free cash flow multiplied by one plus terminal growth, divided by discount rate minus terminal growth, and then discounted back ten years. Fair market capitalization equals that explicit ten-year present value plus discounted terminal value and a same-date balance-sheet adjustment when available. If current cash and debt facts do not share one report date, the table shows the adjustment as unavailable and conservatively applies zero. The share count is derived from the dated market capitalization and share price so US shares and foreign ADRs use a consistent traded-security denominator.

In the reverse-DCF, holding the 9% discount rate and 3% terminal growth fixed, and solving only for one constant growth rate rather than using the base-case growth path, the current market capitalization implies roughly -8.8% annual free cash flow growth for ten years. This is a sensitivity framework, not a price target: the terminal-value share shows how strongly each result depends on assumptions beyond the explicit forecast. Negative margin of safety means the current market capitalization exceeds the scenario value.

Five Value-Investing Lenses

Benjamin Graham Lens

DaVita's balance sheet is stressed by historical standards. Total long-term debt of $10,664 million sits against a shareholders' equity deficit of $(765) million, even though book value is not a clean measure here because goodwill of $7,591 million dominates the asset side and tangible book value is deeply negative. Current assets of $4,190 million cover current liabilities of $2,855 million with room to spare, and trailing-twelve-month operating cash flow of $2,193 million comfortably covers $295 million of first-half debt expense, so the leverage does not threaten near-term solvency. The Graham test that matters more is whether normalized earning power supports the share price: trailing-twelve-month net income of $847 million against a $11,529 million market capitalization is a 7.4% earnings yield before debt costs, which is reasonable but not a screaming bargain. The dated market capitalization sits more than 20% below the deterministic base-scenario fair value, providing a quantitative cushion against permanent-loss scenarios.

Benjamin Franklin Lens

Franklin's discipline here is thrift and opportunity cost. Management has consistently chosen share repurchase over organic reinvestment — $761 million of buybacks in the first half of 2026 versus $272 million of capital expenditure in the same period — and the math favors this choice as long as the buyback price is below intrinsic value. At an average second-quarter repurchase price of approximately $155 per share, the company is acquiring shares below the deterministic base-scenario per-share fair value, so the opportunity cost of capital is positive. The risk is the opposite: if the dated market price of $180.70 already prices in the base-scenario cash-flow trajectory, then continued buybacks at this level destroy capital. Franklin would also note that the company is paying 5.43% on its debt to fund buybacks that earn a free-cash-flow yield of roughly 14% before interest; that spread is the real arbitrage, and it remains wide as long as refinancing can be done at current rates.

Warren Buffett Lens

Buffett would focus on owner earnings, moat, and management integrity. The free-cash-flow proxy of $1,610 million trailing twelve months over a $11,529 million dated market capitalization is a 14% owner-earnings yield, but it sits on top of $10,664 million of long-term debt, so the equity-level yield is roughly 25% — meaningful, but the debt layer is what makes the bet. The moat is the U.S. dialysis duopoly structure and the patient population that requires treatment three times per week for life; the recurring nature of the demand is the closest thing to a toll bridge in U.S. healthcare. Management has been an aggressive capital returner rather than an aggressive acquirer, which Buffett would generally approve of, but the equity-deficit balance sheet is unusual and reflects years of buybacks that have outstripped retained earnings accumulation. The Berkshire Hathaway standstill agreement and share repurchase agreement filed as exhibits are concrete indicators of a sophisticated shareholder base.

Charlie Munger Lens

Munger would invert the thesis and ask what could make it wrong. The most plausible permanent-loss path is a regulatory shock that bundles ESKD into Medicare Advantage at lower effective reimbursement rates than the current Medicare FFS rates, since commercial payors today pay meaningfully more than Medicare and that mix premium is the main lever for above-cost-of-capital returns. A second risk is the GLP-1 / SGLT2 demand-displacement scenario flagged in the 10-K: if these therapies materially slow kidney disease progression, the long-tail dialysis population shrinks. A third is the debt stack: $10,664 million of long-term debt at a 5.43% effective rate, with $4,554 million maturing in 2030 alone, requires refinancing in a higher-rate environment, and the operating leverage runs the wrong way if rates spike. The inversion: this is a story where the bull case is roughly a 4% free-cash-flow grower at a 9% discount rate, and any combination of demand shrinkage, reimbursement cuts, or refinancing stress moves the company toward the bear scenario quickly.

Li Lu Lens

Li Lu would test whether this fits the circle of competence and whether the business has a durable cultural advantage. The business is well understood: regulated recurring healthcare service revenue with high fixed-cost leverage. The cultural durability is harder to verify — the leadership team has been stable across reporting periods, but the equity-deficit balance sheet and aggressive buyback culture suggest a financial-engineering orientation rather than a founder-operator orientation. The permanent-loss control question is whether a 30% drawdown in the share price would force management into bad outcomes; given the leverage and the 2030 debt maturity wall, a sharp drawdown combined with a credit-spread blowout would be the dangerous scenario. Within the circle of competence, this is a recognizable cash-flow business with a clear regulatory boundary and a known competitive set, but the balance-sheet structure and the buyback culture are not typical of the highest-quality compounders.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

Three observable thesis breakers would force a conclusion change. First, a Medicare or Medicare Advantage reimbursement rule change that materially reduces the commercial rate premium — observable in any CMS rule notice that compresses the MA-ESRD benchmark. Second, a measurable slowdown in U.S. dialysis patient growth or treatment counts, observable in quarterly U.S. dialysis revenue trends and in the segment's patient disclosures. Third, a refinancing event in which the company is unable to roll its $4,554 million of 2030 maturities at a rate near the current 5.43% effective rate — observable in subsequent debt issuance pricing and credit-spread behavior. The most likely wrong assumption is that 5% revenue growth translates into similar free-cash-flow growth; the trailing-twelve-month free-cash-flow figure of $1,610 million versus the comparable 2025 figure shows that working-capital swings and capex timing can decouple revenue from cash.

The available evidence does not break cleanly into positive and negative signals. The 2025 cybersecurity incident inflated the comparison base, so first-half 2026 cash flow benefits from a one-time normalization tailwind rather than underlying growth; the same normalization means the 5.2% revenue growth is the cleaner read. The IKC and international segments are not yet self-funding, and the 10-K flags GLP-1 / SGLT2 demand risks without quantification. The market-derived share count used in the deterministic calculation (approximately 63.8 million) is meaningfully lower than the diluted weighted-average count for the second quarter (66.1 million), and a re-purchase of the remaining authorization would push the actual share count toward that market-derived figure.

Investment Conclusion

DaVita passes the Graham test on balance-sheet resilience and the Fisher test on recurring-demand quality, but the equity-deficit balance sheet and the leveraged buyback structure are not the cleanest configuration for a permanent-loss-averse investor. The dated market capitalization of $11,529 million sits more than 20% below the deterministic base-scenario fair value, providing a quantitative margin of safety, and the dated market price appears to embed a slow-decay free-cash-flow scenario that is more conservative than the company's recent run rate. Verdict: attractive with a margin of safety, contingent on debt refinancing in 2030 at acceptable rates, regulatory stability in Medicare and Medicare Advantage, and continued U.S. dialysis patient growth. The investment is not a high-quality compounder in the classic sense — it is a high-cash-flow, high-leverage, high-buyback business that the market is currently pricing at a discount to a reasonable base case.

---

This analysis is for educational and informational purposes only and is not a recommendation to buy or sell any security. All figures are derived from publicly filed SEC documents and dated market data; no private information or forward-looking company guidance was used. Past performance does not guarantee future results, and securities can lose value.

This article is for research and educational purposes and does not constitute personalized investment advice.